Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sarepta reports robust earnings, poised for gene therapy milestone

Sarepta Therapeutics delivered strong financial performance in Q4 2022, driven by revenue growth and positive market reception of its RNA-based PMO therapies.
While facing challenges in managing expenses and navigating regulatory uncertainties, the company is strategically positioned to capitalize on growth opportunities in gene therapy and market expansion.
By focusing on innovation, operational readiness, and market access, Sarepta aims to secure a leading position in Duchenne muscular dystrophy treatment and drive sustainable revenue growth.

Sarepta Therapeutics exceeds Q1 revenue expectations, poised for growth

Sarepta Therapeutics delivered strong financial results in Q1 2023, exceeding expectations and showcasing market confidence in their growth trajectory.
The company's proactive approach to patient access, payer engagement, and therapy development highlights their commitment to addressing unmet medical needs and advancing innovative treatments.
While facing pricing challenges and regulatory decisions, Sarepta's focus on research, partnerships, and therapy expansion presents opportunities for sustained growth and impact.
With a robust pipeline, positive payer discussions, and ongoing studies, Sarepta is poised to make a significant difference in treating rare diseases and improving patient outcomes.

Sarepta Therapeutics excels in Q2 with ELEVIDYS approval and patient-focused strategies

Sarepta Therapeutics demonstrated strong performance in Q2 2023 with positive revenue growth and progress in clinical studies and commercial activities.
Despite challenges in administrative processes and label expansion, the company's focus on patient care and operational efficiency remains a key strength.
Opportunities lie in broadening therapy access, addressing limitations, and streamlining patient access post label expansion for enhanced market reach and treatment efficiency.

Sarepta Therapeutics excels in Q3 earnings, eyes label expansion

Sarepta Therapeutics delivered robust financial performance in Q3 2023, driven by the success of ELEVIDYS and PMOs. Despite challenges in regulatory processes and market competition, the company's strategic focus on label expansion and patient access presents significant growth opportunities.

Sarepta Therapeutics reports robust Q4 earnings and targets pipeline expansion

Sarepta Therapeutics delivered strong financial results in Q4 2023, showcasing revenue growth and profitability. Despite facing challenges such as potential margin declines and clarity issues, the company is well-positioned to capitalize on opportunities for pipeline advancement and expansion.

Sarepta Therapeutics excels in Q1 earnings, eyes label expansions

Sarepta Therapeutics delivered strong financial performance in Q1 2024, driven by robust revenue growth and steady demand for key products like ELEVIDYS.
The company's strategic focus on label expansions and innovative R&D efforts positions it well for future success in addressing unmet medical needs and driving market expansion.
While facing challenges in patient demographics and operational readiness, Sarepta remains well-capitalized and poised to capitalize on upcoming opportunities for growth and market leadership.

Sarepta Therapeutics reports robust Q2 revenue and eyes therapy expansion

Sarepta Therapeutics is experiencing strong revenue growth driven by ELEVIDYS, with a focus on patient outcomes and manufacturing capacity. Challenges include addressing bottlenecks and patient prioritization, while opportunities exist in therapy development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT), which had a lot riding on its gene therapy candidate for treating Duchenne muscular dystrophy in the new year, are sinking. What Happened: Cambridge, Massachusetts-based Sarepta announced topline results from Part 1 of the Phase 2/3 study of SRP-9001, its investigational gene therapy to treat DMD, showing the study didn't achieve statistical significance on the primary functional endpoint of improvement in North Star Ambulatory Assessment, or NSAA, total score compared to placebo at 48 weeks after the treatment.

Sarepta Falls 50% To 10-Month Low After DMD Gene Therapy Study Misses Primary Endpoint

CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 11, 2021 at 10:00  a.m. E.T. /7:00 a.m. P.T. Following the presentation there will be a Q&A session starting at 10:20 a.m. E.T. /7:20 a.m. P.T.

Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Sarepta Therapeutics on Thursday announced mixed results for its gene therapy targeting a form of muscular dystrophy, leading SRPT stock to plummet. Rival Solid Biosciences also fell.

Sarepta Crashes On Mixed Results For Gene Therapy In Muscular Dystrophy

Sarepta Therapeutics Inc. shares lost more than half their value in after-hours trading Thursday, after the company said a drug candidate produced mixed results in a clinical study.

Sarepta stock plunges more than 50% after mixed results from drug study

-- Study met the primary biological endpoint of micro-dystrophin protein expression at 12 weeks post-treatment, as measured by western blot, in SRP-9001-treated participants versus placebo -- -- SRP-9001-treated participants showed an increase in NSAA total score compared to placebo at 48 weeks; however, the study did not achieve statistical significance on the primary functional endpoint of improvement in NSAA total score compared to placebo at 48 weeks post-treatment --

Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

Amicus Therapeutics

Biopharma stocks are risky investment bets that sway wildly in reaction to catalytic events. Binary events scheduled for Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Sarepta Therapeutics Inc (NASDAQ: SRPT) render their stocks as top picks for the first half of 2021, according to an analyst at BofA Securities.

Sarepta, Amicus Top Biotech Picks Ahead Of Key Binary Events: Analyst

MENLO PARK, Calif.--(BUSINESS WIRE)---- $SRPT #PrecisionOncology--Personalis Announces the Launch of SHERPA™ for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development

Personalis Announces the Launch of SHERPA™ for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development

-- Ian Estepan named chief financial officer -- Dallan Murray named chief commercial officer -- Louise Rodino-Klapac, Ph.D., named chief scientific officer -- Ty Howton, general counsel, to retire from Sarepta  -- Ryan Brown named interim general counsel

Sarepta Therapeutics Announces Executive Management Changes

Sarepta's (SRPT) ongoing phase II study data supports continued dose escalation of SRP-5051 and suggests improved efficacy on lower doses compared to Exondys 51.

Sarepta (SRPT) DMD Study Shows Proof of Concept for SRP-5051

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on MOMENTUM Multiple-Ascending Dose Study of SRP-5051 for Duchenne Muscular Dystrophy Conference (Transcript)

-- Results from the multiple - ascending dose trial demonstrate proof-of-concept for SRP-5051 and support continued dose escalation -- -- At a total dose exposure approximately 10x lower than eteplirsen, SRP-5051 at 20 mgs/kg showed enhanced tissue exposure, greater exon skipping, and greater dystrophin production with no negative renal or other laboratory findings --

Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

Sarepta Therapeutics (SRPT) Up 8.9% Since Last Earnings Report: Can It Continue?

CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Dec. 7, 2020 at 8:30 am Eastern Time (ET), it will host a webcast and conference call to present interim data from the MOMENTUM study, a multiple-ascending dose clinical trial of SRP-5051 for the treatment of Duchenne muscular dystrophy. SRP-5051 is the first investigational treatment using Sarepta's next-generation PPMO platform, which is designed around a proprietary cell-penetrating peptide conjugated to Sarepta's phosphorodiamidate morpholino oligomer (PMO) backbone with the goal of increasing drug concentration in muscle tissue.

Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy

Sarepta Therapeutics, Inc. (SRPT) Presents at Evercore ISI HealthCONx Conference - (Transcript)

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Wednesday, Dec. 2, 2020 at 3:30 p.m. E.T.

Sarepta Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference

-- Sarepta is h onored to be recognized for offering a range of benefits and work-life resources to employees and supporting the local community -- -- Rankings based on confidential survey information submitted by employees to independent research company --

Sarepta Therapeutics Named One of The Boston Globe's Top Places to Work 2020

Credit Suisse

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Credit Suisse 29th Annual Virtual Healthcare Conference (Transcript)

We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always available for the general crowd. This doesn't mean that they don't have occasional colossal losses; they do (like Peltz's recent General Electric losses). However, it is still a good idea to keep an eye on hedge fund activity. With this in mind, as the current round of 13F filings has just ended, let's examine the smart money sentiment towards Sarepta Therapeutics Inc (NASDAQ:SRPT).

Sarepta Therapeutics Inc (SRPT): Are Hedge Funds Right About This Stock?

Sarepta (SRPT) Q3 revenues increase year over year.

Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q3 2020 Results - Earnings Call Transcript

Sarepta Therapeutics reported third-quarter losses of $1.42 per share on $121.4 million in sales late Thursday. But SRPT stock was flat in extended trades.

Sarepta Therapeutics Posts Mixed Third Quarter As Sales Miss

-- Dosing with SRP-9001 commercial-process material to proceed following discussions with U.S. FDA -- -- Clinical d osing is expected to begin b efore the end of 2020 --

Sarepta Therapeutics to Commence Dosing of the Next Study with Commercial Process Material for the SRP-9001 Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference on Monday, November 9, 2020 at 3:30 p.m. E.T.

Sarepta Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference

A Relative Strength Rating upgrade for Sarepta Therapeutics shows improving technical performance. The post Sarepta Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating appeared first on Investor's Business Daily.

Sarepta Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2020 financial results after the Nasdaq Global Market closes on Thursday, November 5, 2020. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2020 financial results and to provide a corporate update.

News for Sarepta Therapeutics Stock (SRPT)